9 news items
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
ZLAB
20 May 24
or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
ZLAB
14 May 24
or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPA
ZLAB
12 May 24
of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
ZLAB
2 Apr 24
Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
NVCR
ZLAB
27 Mar 24
of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on Zai Lab's expectations and assumptions
018vffw6rtu4v69oao2fzklf06en43rm42c2vcfw6m9317bvhhj5nf90
ZLAB
13 Mar 24
Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward
hhhfxw13b2pxd6u6fqo4c285z1wmeaayw7g9cczmr4pgr8fnctlilq hrjwr
ZLAB
6 Mar 24
or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press
czvvjo96d9l 5myrx9gxahd0xxkhj
ZLAB
27 Feb 24
of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking
necl7r7vsi4zm19g382jz1zpa8yo4f27u75d5n
A
ACAD
ACHC
27 Feb 24
earnings at $0.06 per share on revenue of $6.44 billion.
• Assured Guaranty
- Prev
- 1
- Next